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Edited by Giulio Superti-FurgaAbstract FTY720 is a novel immunomodulatory drug eﬃca-
cious in the treatment of multiple sclerosis. The drug is converted
in vivo to the monophosphate, FTY720-P, by sphingosine kinase
2. This conversion is incomplete, suggesting opposing actions of
kinase and phosphatase activities. To address which of the
known lipid phosphatases might dephosphorylate FTY720-P,
we overexpressed the broad speciﬁcity lipid phosphatases
LPP1–3, and the speciﬁc S1P phosphatases (SPP1 and 2) in
HEK293 cells, and performed in vitro assays using lysates of
transfected cells. Among LPPs, only LPP3 was able to dephos-
phorylate FTY720-P; among SPPs, only SPP1 showed activity
against FTY720-P. On intact cells, LPP3 acted as an ecto-phos-
phatase or FTY720-P, thus representing the major phosphatase
involved in the equilibrium between FTY720 and FTY720-P ob-
served in vivo.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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FTY720 is an immunomodulatory agent with a novel mode
of action, sequestering lymphocytes from blood and spleen
into secondary lymphoid organs, thereby preventing their
migration to sites of inﬂammation [1]. In addition to the eﬀects
on lymphocyte recirculation, the drug preserves vascular integ-
rity by enhancing endothelial barrier function [2]. FTY720 is
currently in clinical phase 3 trials for the treatment of multiple
sclerosis.
Given its structural analogy to sphingosine (Sph), FTY720 is
phosphorylated in vivo by sphingosine kinases (SPHKs), in
particular the type 2 enzyme [3,4]. The phosphate FTY720-P
binds to four G protein-coupled sphingosine 1-phosphate
(S1P) receptors [5,6]. Most importantly, it acts as a high-aﬃn-
ity agonist at S1P1 on thymocytes and lymphocytes, thereby
inducing aberrant internalization of the receptor. This renders
the cells unresponsive to the serum lipid sphingosine 1-phos-Abbreviations: Cer, ceramide; DHS1P, dihydro-sphingosine-1-phos-
phate; LPA, lyso-phosphatidic acid; LPP, lipid phosphate phospho-
hydrolase; S1P, sphingosine-1-phosphate; SM, sphingomyelin; SPHK,
sphingosine kinase; Sph, sphingosine; SPP, sphingosine-1-phosphate
phosphatase
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doi:10.1016/j.febslet.2007.05.069phate (S1P), depriving them from an obligatory signal to
egress from lymphoid organs [1].
When FTY720 is applied to animals or to man, rapid phos-
phorylation to the monophosphate occurs [5,6]. Conversion to
FTY720-P is not complete, a steady state between phosphory-
lated and non-phosphorylated drug being reached; e.g., in the
rat a ratio of FTY720/FT720-P of 1:4 is reached within 1 h,
lasting for at least 6 h [6]. This is suggestive of opposing ac-
tions of kinase(s) and phosphatase(s) that produce and cleave
FTY720-P, respectively. While the responsible kinase
(SPHK2) has been identiﬁed [3,4], the nature of dephosphoryl-
ating activities acting on FTY720-P was unknown so far.
Interestingly, Mandala et al. [6] noted that FTY720-P is not
cleaved to FTY720 by rat blood ex vivo, indicating dephos-
phorylation outside blood.
S1P is known to be a substrate for various lipid phospha-
tases including the S1P-speciﬁc phosphohydrolases SPP1 and
SPP2 [7,8], and the broad speciﬁcity lipid phosphohydrolases
(LPP1–3) [9]; in addition, S1P lyase is responsible for the irre-
versible cleavage of S1P to ethanolamine phosphate and hexa-
decenal [10]. In contrast to S1P, FTY720-P was shown to be
stable upon incubation with active SPL, suggesting that SPL
is not responsible for metabolism of the drug [11].
In this study, we determined whether FTY720-P might func-
tion as a substrate for lipid phosphatases. We show that
among the panel of known lipid phosphatases, the ecto-phos-
phatase LPP3 is able to dephosphorylate FTY720-P. Among
SPPs, only SPP1 showed moderate activity against FTY720-
P as a substrate, but due to its intracellular location is unlikely
to contribute to the balance between FTY720 and FTY720-P
in the extracellular space.2. Materials and methods
2.1. Cell culture and materials
Human umbilical vein endothelial cells (HUVEC) were cultured at
37 C and 5% CO2 in EGM-2 medium (Clonetics). HEK293 cells
were cultured in DMEM H21 containing 10% fetal calf serum and
non-essential amino acids (Gibco).
Nitrobenzo-2-oxa-1,3-diazole (NBD) labeled derivatives were pre-
pared as described [12,13]. [3-3H] S1P (20 Ci/mmol), [4,5-3H] dihy-
dro-S1P (40 Ci/mmol), and [3-3H] sphingosine (20 Ci/mmol) were
from American Radiolabeled Chemicals. Tritium labeled lysophospha-
tidic acid (1-oleoyl,[oleoyl-9,10-3H(N)] LPA, 47 Ci/mmol) was from
Perkin–Elmer. [3-3H] FTY720 (102 Ci/mmol) and [3-3H] FTY720
phosphate (54 Ci/mmol) were synthesized at Novartis.
For metabolic conversion experiments, HUVEC at 80% conﬂuence
in 6-well plates were incubated for 1 or 3 h at 37 C in 1 ml medium
per well containing 2 lCi of either [3H] Sph (100 nM), [3H]FTY720
(20 nM), [3H] S1P (100 nM), or [3H] FTY720-P (36 nM). Alternatively,blished by Elsevier B.V. All rights reserved.
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their corresponding NBD-labeled phosphates, were added to the cells
at 2 lM.
2.2. Transient transfection of HUVEC and HEK293
N-terminally Flag-tagged LPP1, LPP2, and LPP3 were ampliﬁed by
PCR from pooled human kidney and lung cDNA. The PCR fragments
obtained were subcloned into pcDNA3.1 (Invitrogen). For EGFP-
tagged expression, non-tagged ORFs were transferred to pEGFP-c2
(Clontech). SPP1 and SPP2 ORFs were cloned as previously described
[14]. For EGFP-tagged expression, ORFs in pcDNA6.2-DEST (Invit-
rogen) were subcloned into pEGFP-c2. Full-length cDNAs encoding
human LPP1 and 3, and mouse LPP3, SPP1 and 2 in pCMV-SPORT6
were obtained from Invitrogen.
HUVEC were seeded overnight in 6-well plates to reach 60% conﬂu-
ence. Transient transfection of HUVEC with plasmids encoding LPPs
and SPPs was done with LipofectAMINE and PLUS reagent (Invit-
rogen). Cells were incubated with transfection mixtures containing
0.5 lg of DNA, 6 ll of PLUS reagent, and 4 ll of LipofectAMINE
in a total volume of 1 ml of medium 199 per well for 105 min. Cells
were washed with the complete medium and cultured for 20 h before
proceeding with further investigations. For immunoﬂuorescence stud-
ies, HUVEC were grown on Lab-Tek glass chamber slides (Nunc) and
transfected with plasmids at suboptimal amounts (0.25 lg per 1 ml of
transfection mixture). HEK293 cells were transfected using the calcium
phosphate method.
To estimate eﬃciency of transfection, subcellular localization of
EGFP-tagged phosphatases or uptake of NBD-labeled lipids, living
cells were analyzed with an inverted microscope equipped with a high
resolution microscopy camera (Zeiss) as well as oil DIC objectives
(Plan-Neoﬂuar 40·/1.30 and Plan-Apochromat 63·/1.40). Excitation/
emission ﬁlter settings were 450–490/515–565 nm.2.3. In vitro phosphatase assays
Lipid phosphatase activity was estimated by the degree of dephos-
phorylation of radiolabeled or NBD-labeled substrates. Transfected
HEK293 cells were scraped into PBS, collected by centrifugation and
resuspended in lysis buﬀer (50 mM HEPES, pH 7.3, containing
150 mM NaCl, 20% glycerol, 1 mM EDTA, 1 mM DTT and protease
inhibitor mix from Roche), followed by freeze–thaw cycles. HEK293
lysates (5 lg of total protein) were mixed with substrates: (i) [3H]
S1P, 0.25 lM, 0.5 lCi; (ii) [3H] dihydro-S1P (0.08 lM, 0.5 lCi); each
plus cold S1P at 1 lM, prepared in 0.1% fatty acid-free BSA (Sigma)
as described [7]; (iii) [3H] LPA (0.1 lM, 0.5 lCi), balanced with
2 lM cold lyso-phosphatidic acid (LPA), prepared with 0.1% Triton-
X100; (iv) [3H]FTY720-P (0.3 lM, and 1.7 lCi) prepared with bovine
serum albumin. For NBD-labeled substrates, 50 lg of total proteinFig. 1. Metabolic conversion of FTY720 by cells in culture. (A) HUVEC w
respectively) followed by lipid extraction and separation of products by TLC
in HUVEC and HEK293 cells. Cells were exposed to NBD-labeled derivative
Sph, NBD-S1P, NBD-SM; NBD-std2: NBD-labeled FTY720 and FTY720-were mixed with 5 lM NBD-S1P or NBD-FTY720-P in 0.1% fatty
acid-free BSA. Incubations were done in total reaction volumes of
100 ll at 37 C for 15 min.
For analysis, 400 ll PBS was added to the reaction mixtures and lip-
ids were extracted by adding of 707 ll of chloroform/methanol/HCl/
5 M NaCl (300:300:7:100 v/v) and mixing. After sonication, phases
were separated by centrifugation, and the organic phase was recovered,
dried, and dissolved in chloroform/methanol (19:1, v/v). The labeled
lipids were resolved by thin-layer chromatography (TLC) on SilicaGel
60 TLC plates (Merck) with 1-butanol/acetic acid/water (3:1:1, v/v) or
CHCl3/MeOH/H2O/NH4OH (28% w/w) 200:150:29:1 as previously de-
scribed [13]. In these systems, NBD-labeled FTY720 derivative and
[3-3H]FTY720 as well as their corresponding phosphates co-migrate.
Radiolabeled S1P and FTY720-P were identiﬁed by co-migration with
unlabeled standards, visualized using vanillin/sulfuric acid [15]. TLC
plates were exposed to Kodak BioMax MR Film at 80 C; for
NBD-labeled lipids, plates were photographed and bands quantiﬁed
by using AlphaImager 2200 (Alpha Innotech). S1P phosphatase activ-
ity was expressed as nmol of sphingosine formed per minute per milli-
gram of total protein. Protein concentrations in cell lysates were
determined using Bradford reagent (BioRad).3. Results and discussion
3.1. Metabolic conversion of FTY720 in cell cultures
Primary endothelial cells (HUVEC) in culture were incu-
bated with [3H]FTY720, and for comparison with [3H]Sph
for 1 and 3 h, followed by lipid extraction and separation of
products by TLC (Fig. 1A). While Sph was converted by the
cells to S1P, ceramide (Cer), and sphingomyelin (SM) as prod-
ucts expected from sphingolipid metabolism [13,16], FTY720
was converted to FTY720-P as the only detectable product
(Fig. 1A) even after 24 h of incubation (data not shown).
The low rate of [3H] FTY720 phosphorylation in HUVEC
was strongly increased in SPHK2-overexpressing cells in com-
parison to the vector-transfected cells (data not shown). A sim-
ilar conversion pattern was seen when using as substrates a
ﬂuorescently labeled FTY720 derivative [12] and for compari-
son a ﬂuorescently labeled Sph derivative [13]; while the NBD-
Sph derivative was rapidly metabolized to its phosphate and to
corresponding Cer and SM species, the NBD-FTY720 deriva-
tive was phosphorylated, only (Fig. 1B). Similar metabolicere incubated with [3H] Sph or [3H] FTY720 (2 lCi; 100 and 20 nM,
. (B) Metabolic conversion of NBD-labeled FTY720 (2 lM) derivative
s for 1 and 3 h. NBD-std1: NBD-labeled standards as NBD-Cer, NBD-
P derivatives. The percentage of substrate conversion is indicated.
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HEK293 cells (Fig. 1B).
3.2. Identiﬁcation of lipid phosphatases able to dephosphorylate
FTY720-P
Incubation of FTY720-P (1 lM) with fresh whole human
blood ex vivo led to marginal dephosphorylation to FTY720,
with about 4% degradation occurring after 5 h at 37 C as
measured by LC/MS (see Ref. [15] for method). This is line
with data from Mandala et al. [6] on rat blood and their sug-
gestion that dephosphorylation of FTY720-P occurs outside
blood. To identify any tissue associated phosphatase that
might cleave FTY720-P, we examined the known lipid phos-
phatases. First, we transiently expressed EGFP-tagged phos-
phatases LPP1, LPP2, LPP3, or SPP1 and SPP2 in HEK293
cells in order to compare their subcellular localizations
(Fig. 2A) The observed ﬁne membranous reticular patterns
for EGFP-SPP1 and -SPP2 were consistent with endoplasmic
reticulum localization, as described before [16]. EGFP-LPP1
also showed predominantly intracellular ER-like localization;
in addition, plasma membrane ﬂuorescence was readily visible
in part of the cells. In contrast, EGFP-LPP2 and -LPP3 exclu-
sively localized to the plasma membrane. An estimation of
ﬂuorescence intensity of transfected cells revealed similar
expression levels for the EGFP-tagged phosphatases
(Fig. 2B). Subcellular localization of EGFP-tagged LPPs and
SPPs in HUVEC was in agreement with the results obtained






Fig. 2. Subcellular localization of EGFP-LPPs and -SPPs in HEK293 cells. (A
LPP1, 2 and 3 (a–c) and EGFP-SPP1 and 2 (d, f). (B) Quantiﬁcation of EGFP
each replicate were imaged and ﬂuorescence of at least 100 cells were quantLysates of phosphatase-expressing HEK293 cells were used
to estimate the activity of the ﬁve enzymes against FTY720-
P. For comparison, we included S1P, dihydro-sphingosine-1-
phosphate (DHS1P) and LPA as substrates in the phosphatase
assays. Human lipid phosphatases were expressed either as un-
tagged proteins or as Flag- or EGFP-tagged enzymes; untagged
mouse LPP3 (mLPP3) was expressed in addition. All human
LPPs as well as mLPP3 had strong phosphatase activity against
[3H]LPA yielding monoacylglycerol (MG), in agreement with
previous reports [9]; SPP1 and 2 failed to cleave LPA, again
in line with published data [17] (data not shown). All untagged
lipid phosphatases readily cleaved both [3H]S1P and [3H]
DHS1P as substrates; among the LPPs, LPP3 exhibited the
strongest activity. Using [3H]FTY720-P as a substrate we found
that LPP3, both human and mouse variants, were able to
dephosphorylate FTY720-P (Fig. 3). Among SPPs, only SPP1
showed moderate activity against FTY720-P; similar results
were obtained when mouse variants of SPP1 and SPP2 were
used (data not shown). Modulation of the phosphatase assay
conditions such as increased amount of cell lysates, prolonged
reaction time or overexpression in other vectors (Flag- or
EGFP-tagged enzymes) did not change the outcome (data
not shown). For the ﬂuorescently labeled derivative of
FTY720-P, only lysates of LPP3 transfected cells showed
detectable turnover of the substrate. To conclude, FTY720-P
is a substrate for LPP3 and, to a lesser degree, for SPP1.
The speciﬁc activities of LPP3 and SPP1 against [3H]
















) Representative live-cell images HEK293 cells transfected with EGFP-
intensity across transfected cell. Multiple ﬁelds of transfected cells for
iﬁed.
Fig. 3. Phosphatase assays in vitro. Phosphatase activity was measured in lysates of HEK293 cells overexpressing individual LPPs and SPPs using
[3H]FTY720-P (1.7 lCi, 0.3 lM) or NBD-FTY720-P (5 lM). Expression vectors were either pcDNA3.1 or pCMV-SPORT6, as indicated. Lipids
were extracted and separated by TLC. The percentage of substrate conversion is indicated.
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S1P, LPP3 and SPP1 activities were 2.85 ± 0.075 nmol/min/mg
and 2.70 ± 0.15 nmol/min/mg (mean ± SD, n = 4). Thus, both
LPP3 and SPP1 exhibited lower dephosphorylation activities
against [3H]FTY720-P in comparison to [3H]S1P.
3.3. Ecto-phosphatase activity of LPP3 in intact cells
LPP3, being located in the plasma membrane, acts as ecto-
phosphatase against its natural substrates. Here, we asked
whether the enzyme expressed on HUVEC would cleave
FTY720-P. Lipid phosphates, due to their negative charge,
are unlikely to be taken up into cells, while the molecules
may readily enter cells after dephosphorylation. Use of ﬂuores-
cently labeled lipid substrates allows to check for uptake and
accumulation of ﬂuorescent non-phosphorylated products in
living cells.
HUVEC were transfected with the empty vector or untagged
LPP1-, LPP2-, and LPP3-overexpressing constructs; the next
day, cells in culture were exposed for 1 h to 2 lM of NBD-
S1P and NBD-labeled FTY720-P, followed by microscopic
examination of cell-associated ﬂuorescence and lipid extraction
from the cells. The eﬃciency of HUVEC transfection was
about 40% as estimated by counting the percentage of
EGFP-expressing cells after parallel transfection with
pEGFP-c2 vector (data not shown). As shown in Fig. 4A, cells
overexpressing LPP3 (but not LPP1 or LPP2) featured strong
intracellular ﬂuorescence after exposure to NBD-S1P and, to a
lesser but signiﬁcant extent, after treatment with the labeled
FTY720-P derivative. Lipid separation by TLC conﬁrmed en-
hanced uptake of NBD-Sph and NBD-labeled FTY720 deriv-
ative into LPP3-transfected cells as compared to cells
transfected with vector or LPP1 or 2 (Fig. 4B). Part of
NBD-Sph was further converted to NBD-Cer and NBD-SM,
while NBD-FTY720 was not converted to any Cer- or SM-like
metabolites in line with the results shown in Fig. 1. Similar re-
sults were obtained with LPP3-overexpressing HEK293 cells
exposed to the NBD-labeled FTY720-P derivative; higher eﬃ-
ciency of transfection of HEK293 cells (in the range of 80–
90%) in comparison to HUVEC was translated into stronger
ecto-phosphatase activity against the FTY720-P derivative fol-
lowed by an eﬃcient uptake and intracellular accumulation of
its non-phosphorylated form (Fig. 4C). Of note, low amountsof NBD-S1P and NBD-FTY720-P derivative were seen to be
metabolized by the vector-transfected cells in culture, also,
both in HUVEC and HEK293 cells (Figs. 4B and C). This
may be attributed to endogenous LPP3 activity. In support,
real-time PCR analysis revealed that both HUVEC and
HEK293 cells express endogenous LPP3 (data not shown).
Interestingly, in spite of the fact that only 40% of HUVEC
were transfected, nearly all cells after exogenous addition of
NBD-S1P were ﬂuorescent (Fig. 4A). To investigate this phe-
nomenon in more detail, the amount of LPP3 plasmid used
for transfection was titrated down, which consequently re-
duced the transfection eﬃciency and the LPP3 expression lev-
els (data not shown). Using this approach, we found that LPP3
activity on NBD-S1P in one cell aﬀects the ﬂuorescence uptake
by cells in the neighborhood (Fig. 4D). At the highest expres-
sion level of LPP3, the amount of Sph produced by the popu-
lation of transfected cells seems to be suﬃcient to detect
ﬂuorescence in all cells. The same phenomenon was seen when
the NBD-labelled FTY720-P derivative was applied to cells.
However, limiting LPP3 hydrolytic potential towards NBD-
FTY720-P accounted for lower intracellular ﬂuorescence lev-
els.
To further substantiate these results and to exclude any po-
tential eﬀect of the NBD-label on lipid traﬃcking, we repeated
the experiments using tritium labeled S1P and FTY720-P. In
line with the results described above, when LPP3-overexpress-
ing cells were exposed to [3H] S1P, strong accumulation of
intracellular [3H]Sph was detected in comparison to the vector
transfected cells (Fig. 4E); [3H] Sph was further converted to
[3H] Cer and [3H] SM. Signiﬁcant amount of [3H] Sph was
as well detected in the conditioned medium of LPP3-transfec-
ted cells. Furthermore, LPP3-overexpressing cells were able to
dephosphorylate [3H] FTY720-P and, consequently, accumu-
lated the non-phosphorylated [3H] FTY720. Thus, the data
demonstrate that LPP3 functions as ecto-phosphatase for
FTY720-P (and S1P) thereby regulating levels of FTY720-P
in proximity to the membrane, as well as uptake and, there-
fore, intracellular levels of non-phosphorylated FTY720.
In summary, we here identiﬁed two phosphatases, LPP3 and
SPP1, which are able to cleave FTY720-P. LPP3 is known to
act as an ecto-phosphatase on its natural substrates; here we
demonstrated that LPP3 expressed by cells can cleave
Fig. 4. Analysis of LPP3-promoted lipid uptake and metabolism in intact HUVEC. HUVEC were transfected with the empty vector or untagged
LPP-expression constructs. The next day, cells in culture were exposed for 1 h to 2 lM of NBD-S1P or NBD-labeled FTY720-P derivative followed
by (A) microscopic examination of cell-associated ﬂuorescence, and (B) analysis of the NBD-labeled products by TLC. (C) Similarly to HUVEC,
HEK293 cells were transfected with indicated plasmids followed by lipid extraction and separation of NBD-labeled metabolites by TLC. NBD-std:
NBD-labeled standards (NBD-Cer, NBD-Sph, NBD-S1P, NBD-SM). (D) HUVEC were transfected with increasing amount of LPP3-encoding
plasmid (a, e: 0 lg; b, f: 0.125 lg; c, g: 0.25 lg; d, h: 0.5 lg per 1 ml of transfection mixture); the next day, cells were exposed for 1 h to 2 lM of NBD-
S1P and NBD-labeled FTY720-P derivative followed by microscopic examination of cell-associated ﬂuorescence in living cells. (E) HUVEC were
transfected with empty vector or untagged LPP3-overexpressing plasmid (0.5 lg); the next day, cells in culture were exposed for 1 h to [3H] S1P
(2 lCi, 100 nM) or [3H] FTY720-P (2 lCi, 36 nM) followed by lipid extraction from both cell pellet and culture supernatant medium and separation
of tritium labeled metabolites by TLC. The percentage of substrate conversion is indicated.
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the enzyme that contributes to the equilibration between
FTY720 and FTY720-P in blood and tissues observed
in vivo. SPP1, as an intracellular enzyme, may play a role in
the conversion of FTY720-P within cells.References
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